The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial

OBJECTIVES: The primary objective is to determine the efficacy of a single dose of ivermectin, administered to low risk, non-severe COVID-19 patients in the first 48 hours after symptom onset to reduce the proportion of patients with detectable SARS-CoV-2 RNA by Polymerase Chain Reaction (PCR) test...

Descripción completa

Detalles Bibliográficos
Autores principales: Chaccour, Carlos, Ruiz-Castillo, Paula, Richardson, Mary-Ann, Moncunill, Gemma, Casellas, Aina, Carmona-Torre, Francisco, Giráldez, Miriam, Mota, Juana Schwartz, Yuste, José Ramón, Azanza, José Ramón, Fernández, Miriam, Reina, Gabriel, Dobaño, Carlota, Brew, Joe, Sadaba, Belen, Hammann, Felix, Rabinovich, Regina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7276958/
https://www.ncbi.nlm.nih.gov/pubmed/32513289
http://dx.doi.org/10.1186/s13063-020-04421-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7276958/
https://www.ncbi.nlm.nih.gov/pubmed/32513289
http://dx.doi.org/10.1186/s13063-020-04421-z

Ejemplares similares